Knockdown of Nogo gene by short hairpin RNA interference promotes functional recovery of spinal cord injury in a rat model

GUO-MIN LIU¹, YUN-GANG LUO², JUAN LI³ and KUN XU³

Departments of¹ Orthopedics and ²Stomatology, The Second Hospital of Jilin University, Changchun, Jilin 130041; ³Department of Preventive Medicine, College of Public Health, Jilin University, Changchun, Jilin 130021, P.R. China

Received March 29, 2015; Accepted February 1, 2016

DOI: 10.3892/mmr.2016.5072

Abstract. The specific myelin component Nogo protein is one of the major inhibitory molecules of spinal cord axonal outgrowth following spinal cord injury. The present study aimed to investigate the effects of silencing Nogo protein with shRNA interference on the promotion of functional recovery in a rat model with spinal cord hemisection. Nogo-A short hairpin RNAs (Nogo shRNAs) were constructed and transfected into rats with spinal cord hemisection by adenovirus-mediated transfection. Reverse transcription-polymerase chain reaction and western blotting were performed to analyze the expression of Nogo-A and Growth Associated Protein 43 (GAP-43). In addition, Basso Beattie Bresnahan (BBB) scores were used to assess the functional recovery of rats following spinal cord injury. The results demonstrated that expression of the Nogo-A gene was observed to be downregulated following transfection and GAP-43 expression was observed to increase. The BBB scores were increased following treatment with Nogo shRNAs, indicating functional recovery of the injured nerves. Thus, Nogo-A shRNA interference can knockdown Nogo gene expression and upregulate GAP-43 to promote the functional recovery of spinal cord injury in rats. This finding may advance progress toward assisting the regeneration of injured neurons through the use of Nogo-A shRNA.

Introduction

Spinal cord injury (SCI) is a devastating clinical condition for which there is currently no fully restorative treatment. Following SCI, the resulting scar tissue and myelin debris can produce a hostile environment in which neurite outgrowth and axonal regeneration is hampered by the limited intrinsic regenerative capacity of injured neurons, due to the lack of neurotrophic support and the presence of growth inhibitory molecules in myelin (1,2). Specific myelin components, such as myelin-associated glycoprotein (MAG) and the C-terminal of Nogo-A (Nogo-66), are major inhibitory molecules of spinal cord repair after SCI (3,4).

Nogo protein is a central myelin-derived proteins expressed in the white matter of central neural system (CNS), and has been confirmed to block axon regeneration following injury (5). Three isoforms (Nogo-A, -B, and -C) are generated through alternative splicing and differential promoter usage from a single Nogo gene. The inhibitory action of the Nogo protein is dependent on the Nogo-66 domain, which is present in all three isoforms. Nogo-66 is a 66-amino-acid sequence between N- and C-terminals. Nogo-A exerts its inhibitory effects by binding to the Nogo receptor via the Nogo-66 domain. Studies have shown that the Nogo-66 high-affinity receptor (NgR) is a common receptor of Nogo, MAG and oligodendrocyte myelin glycoprotein (OMgp) (6-14). The NgR is a member of a family of three CNS-enriched glycosyl phosphatidylinositol-linked proteins (6-8). NgR functions as the ligand binding component of a tripartite receptor system consisting of Lingo-1 and tumour necrosis factor (TNF) receptor family members, p75NTR or TROY (9). Inhibition of NgR with function-blocking antibodies or short hairpin RNA interference (shRNA)-mediated knockdown have been reported to demonstrate that NgR is essential for Nogo66, MAG and OMgp inhibitory effects (10-12). NgR mRNA is detected in numerous types of neurons in the CNS and distribution of NgR protein is consistent with its mRNA (13,14). The expression of myelin inhibitors or receptor-related proteins can be knocked down by RNA interference to reduce neuronal apoptosis and promote axonal regeneration after injury (15,16).

Growth Associated Protein 43 (GAP-43), a plasticity and growth protein, is expressed at high levels in neuronal growth cones during development and axonal regeneration (17,18). GAP-43 is a crucial component of the axon and presynaptic terminal, and its nonsense mutation causes defects in motor axon outgrowth and pathfinding (19).

A novel therapeutic strategy is required for neuron regeneration and SCI repair. The aim of the present study was to establish an efficient and highly specific shRNA expression and delivery system to knock down the Nogo gene and to detect effects of the Nogo shRNA system on SCI repair in a rat model.
Materials and methods

Animals. Sprague Dawley rats (n=40; age, 2-3 weeks) were housed at a room temperature of 22±2°C with a 12-h light:dark cycle and free access to food and water. The present study was approved by the Jilin University Animal Ethics Committee (Changchun, China).

Preparation of Nogo-A shRNA. The Nogo-66 gene has 66 amino acids between two transmembrane regions of Nogo proteins. The expression of Nogo-66 has a strong inhibitory effect on CNS regeneration (20). Two specific shRNA sequences were designed to target the cDNA sequence of Nogo-66 (1024-1089 amino acid fragment) and the primers were as follows: Sense, 5'-GGG CGT GAT CCA GGC TATCTTT-3' and antisense, 5'-GAT AGC CTG GAT CAC GCCCTT-3'; sense 5'-GGC GCT CCA TTC AGG GCAATT-3' and antisense, 5'-ATG CCC TGA ATG GGT GCCCTT-3'. Non-effective scrambled shRNA was used as a negative control, and sequences were as follows: Sense, 5'-GGC GGT AGT CAC GGT CAT CT 3'; and antisense, 5'-GGA TCC AAA AAA GAT AGC CTG GAT TCA 3'.

The Exnu-shRNA U6 plasmids pDC316 (Microbix Biosystems Inc., Toronto, ON, Canada) were used as the adenovirus packaging system to package the recombinant pDCU6shNogos, and the resulting recombinant virus (rAdUNogos) was a replication deficient adenovirus due to missing E1/E3 regions.

Interference of the endogenous Nogo gene by adenovirus-mediated Nogo shRNA transfection via local injection in SCI model rats. Sprague Dawley rats (n=40) underwent spinal cord hemisection for modeling of SCI according to the methods of previous studies (21-24). After 7 days, transfection of the recombinant adenovirus carrying pDCU6shNogos into SCI rats was performed by direct local injection of 5 µl rAdUNogos containing 10 µg Nogo shRNA into the spinal cord. The rats were divided randomly into four separate groups as follows: Group A, 10 µg shRNA Nogo1 (rAdUshNogo1); group B, 10 µg shRNA Nogo2 (rAdUshNogo2); group C, 10 µg shRNA Nogo3 (rAdUshNogo3 containing the chaotic sequence) served as the negative control; and group D, model control, saline containing 10 µg empty adenoviral vector.

At 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 days after injection, the animals in each group were narcotized with sodium pentobarbital (30-40 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) and sacrificed by cervical dislocation.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from the spinal cord at the location of the injury 3 days subsequent to injection. Nogo mRNA was detected by RT-qPCR. Briefly, total RNA was transcribed into cDNAs. PCR amplification was performed using cDNA as the template. Nogo-A primers were as follows: Sense, 5'-TCA AAG GTG ACT GAG GCAGC-3' and antisense, 5'-ACT GGG CTG CAC TAC AGAAG-3'. Primers for the internal reference, GAPDH were as follows: Sense, 5'-GGG CCA AAA GGC TCA TAC CAA-3' and antisense, 5'-AAC CTG GTG CTC AGT GTAGC-3'. The PCR system of 30 µl was composed of 2 µl of the cDNA template (100 ng/µl), 3 µl 10X buffer, 0.5 µl Taq DNA polymerase, 3 µl MgCl2, 0.5 µl Taq DNA polymerase, 0.1 µl Pfu DNA polymerase, 2 µl DMSO and double distilled H2O up to 50 µl. The PCR cycling conditions were as follows: 94°C for 5 min; 94°C 30 sec, 55°C for 30 sec, 72°C for 1 min, 30 cycles and 72°C for final extension. The PCR products that were amplified using the Bio-Rad T100 thermocycler (Bio-Rad Laboratories, Shanghai, China) were named U6shNogo1, U6shNogo2, U6shNogo3 and U6shNogo3 containing. Scrambled shRNA was used as the negative control. The U6shNogos were ligated into the pCuri-T vector (Bio Basic Inc., Markham, ON, Canada), and the ligation products were transfected into E. coli DH5α competent cells. The plasmids were extracted and purified using an Aurum Plasmid Mini kit (cat no. 732-6400, Bio-Rad Laboratories). U6shNogos were cut from the T-vector with EcoRI and Sall, and then cloned into the AdMaxTM adenovirus shuttle plasmids pDC316 (Microbix Biosystems Inc., Toronto, ON, Canada), to construct the pDCU6shNogo1, pDCU6shNogo2 and pDCU6shNogo3 (with the scrambled sequence as the negative control) plasmids. The fragment of interest was cut by EcoRI and SalI restriction enzymes for identification. AdMax Systems (Microbix Biosystems Inc., Toronto, ON, Canada) were used as the adenovirus packaging system to package the recombinant pDCU6shNogos, and the resulting recombinant virus (rAdUNogos) was a replication deficient adenovirus due to missing E1/E3 regions.

Western blotting. The Nogo-A protein expression levels of each group were detected by western blotting 3 days after injection. GAP-43 protein expression levels in the shRNA Nogo1 group and the model control 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 days after injection were also determined by western blotting. The procedures were performed according to the manufacturer's protocol (Thermo Scientific Pierce Fast Western Blot kit, ECL substrate; cat no. 35050; Thermo Fisher Scientific, Inc., Waltham, MA, USA) as described previously (25). Briefly, the spinal cord tissues were homogenated and lysed with radioimmunoprecipitation assay buffer. Proteins were separated on a 10% SDS-PAGE gel and electrophoretically transferred to a PVDF membrane. The membranes were blocked with 5% nonfat milk in Tris buffered saline containing 0.1% Tween 20 (TBST) and incubated with primary antibodies against Nogo-A (1:1000, E10-1619, Cell Signaling Technology, MA, USA) and GAP-43 (1:1000, ab22877, Abcam, Cambridge, MA, USA). After washing, the blots were incubated with a horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were visualized using a chemiluminescence detection system (ECL substrate; cat no. 35050; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and densitometric analyses performed using ImageJ software (National Institute of Health, Bethesda, MD, USA).
a polyvinylidene fluoride membrane. Consecutively, the membrane was blocked in 5% skimmed milk (Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China) in PBS-T at room temperature for 2 h, incubated in either anti-Nogo-A (diluted 1:2,000; cat no. sc-25660) or anti-GAP-43 rabbit polyclonal antibodies (diluted 1:500; cat no. sc-10786) all purchased from Santa Cruz Biotechnology, Inc., (Dallas, TX, USA) overnight at 4˚C, incubated in horseradish peroxidase-conjugated anti-rabbit IgG (diluted 1:5,000; cat no. 31460; Thermo Fisher Scientific, Inc.) at room temperature for 1 h, and visualized using enhanced chemiluminescence reagent. β-actin (diluted 1:5,000; cat no. sc-130656) was used as the housekeeping internal reference. Images were analyzed using Image-Pro Plus (version 6.0; Media Cybernetics Inc., Rockville, MD, USA).

In addition, the functional recovery of rats with SCI was assessed through the Basso, Beattie and Bresnahan (BBB) scoring system (26‑30), 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 days after injection. Statistical analysis. Data were analyzed using SPSS statistical software (version 17.0; SPSS, Chicago, IL, USA). Student’s t-test and analysis of variance, with Duncan’s multiple range test post-hoc analysis, were performed for comparison. P<0.05 was considered to indicate a statistically significant difference.
in oligodendrocytes of rAdUshNogo1 group decreased by 29.5% (P<0.05), and rAdUshNogo2 group decreased by 28.2% (P<0.05) (Fig. 3). The shRNAs inhibited Nogo-A expression at the protein level.

**GAP-43 protein blots from rats with SCI following injection with rAdUshNogo1.** The GAP-43 expression levels in the model control and rAdUshNogo1 group increased. The GAP-43 expression level of the rAdUshNogo1 group was significantly increased, and reached the maximum at 7 days. After 2 days, the expression levels of GAP-43 in the rAdUshNogo1 group were markedly higher compared with the model control. After 7 days, the GAP-43 expression levels of the rAdUshNogo1 group and the model control reduced. However, the expression of GAP-43 in the rAdUshNogo1 group was not significantly reduced (Fig. 4).

**Functional recovery of rats with SCI following injection with rAdUshNogo1.** The BBB scores (0-21 points) of the rats were determined using a double-blind method as reported in the literature (31). A lower score indicated more serious injury. Prior to spinal cord hemisection surgery, all rats achieved 21 points in the BBB tests. One day following hemisection, the BBB scores were ~1 for all rats. The BBB scores were significantly increased in the rAdUshNogo1 group on days 6, 8, 10 (P<0.05; Fig. 5) compared with the model control.

**Discussion**

The spinal cord has a limited capacity for regeneration and this is largely attributable to the presence of cellular substrates that are unsuitable for growth. In *vitro* and in *vivo* evidence supports the ability of Nogo-A to inhibit neurite outgrowth (15,32-34).

In the present study, an animal model of SCI was generated, and virus-mediated small hairpin RNAs were injected into the spinal cord region by local injection. Nogo expression in the SCI region was detected by RT-PCR analysis. Compared with the rAdUshNogo3 group (negative control), Nogo mRNA relative expression levels in the SCI region decreased by 45.0% (P<0.05) following injection with rAdUshNogo1 and 40.0% following injection with rAdUshNogo2 (P<0.05). This indicated that the adenoviral vector that was constructed in *vivo* successfully transcribed short hairpin RNAs, which participated in Nogo-transcriptional regulation. rAdUshNogo1 and rAdUshNogo2 effectively suppressed the expression of the Nogo-A gene in *vivo*, and rAdUshNogo3 did not inhibit Nogo-A gene expression, indicating that the designed small hairpins were specific.

GAP-43 is a specific phosphoprotein of neural tissue. It is located in neurons, regenerated Schwann cells and glial cells,
and is considered as the molecular marker of axon growth and plasticity (35,36). High expression of GAP-43 is considered to be typical in the repair of nerves, and is closely associated with neuronal growth within the spinal cord (37,38). In the process of neuronal growth, GAP-43 may affect axon growth by altering G protein activity of the growth cones, which guide axonal extension and growth. The interaction of G protein with its receptor generates inhibitory signals, resulting in the growth arrest of growth cones (39). When GAP-43 and G-protein bind, the disinhibition signal allows the axons to continue growth (39).

In the present study, GAP-43 expression in the spinal cord was increasing following SCI, indicating that GAP-43 participated in the growth and repair of the spinal cord. shRNAs against Nogo-A were injected into the rats with SCI. The experimental animals were divided into the rAdUshNogo1 group and the model control. The rAdUshNogo1 group underwent injection with rAdUshNogo1 for different time points of 1 to 10 days. The relative GAP-43 expression was detected by western blotting, with β-actin was used as a control. The results showed that, GAP-43 expression increased with time and reached a peak at 7 days. The GAP-43 expression of the rAdUshNogo1 group and the model control gradually increased, but the GAP-43 expression of the rAdUshNogo1 group was markedly higher than that of the model control.

In conclusion, the adenoviral vector-mediated Nogo shRNA interference can effectively inhibit the expression of Nogo-A in oligodendrocytes and in rats with SCI, and upregulate the production of GAP-43 in rats with SCI. Knockdown by Nogo shRNAs has the potential to become an effective method for the treatment of SCI.

References


